Metastatic Ureter Urothelial Carcinoma Withdrawn Phase 2 Trials for Aldesleukin (DB00041)

IndicationStatusPhase
DBCOND0110110 (Metastatic Ureter Urothelial Carcinoma)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03935347Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based ChemotherapyTreatment